Reassessment of enfuvirtide's role in the management of HIV-1 infection

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 13, 2008, Pages 2349-2362

  Marr, Patricia ^a   Walmsley, Sharon ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Anti HIV agents; Antiretroviral therapy; Enfuvirtide; Fuzeon; HIV entry inhibitor; HIV fusion inhibitor; HIV infection; Salvage therapy; T 20; Treatment experienced patients

Indexed keywords

ANTIRETROVIRUS AGENT; APLAVIROC; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; ENFUVIRTIDE; ETRAVIRINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; PROTEINASE INHIBITOR; RALTEGRAVIR; RIFAMPICIN; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR; TIPRANAVIR; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BODY FAT DISTRIBUTION; CD4 LYMPHOCYTE COUNT; CHILL; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EMBASE; EOSINOPHILIA; ERYTHEMA; FEVER; GASTROINTESTINAL SYMPTOM; GLOMERULONEPHRITIS; HEMOPHILIA; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; HYPOTENSION; IMMUNE COMPLEX DISEASE; INJECTION SITE INDURATION; INJECTION SITE NODULE; INJECTION SITE REACTION; KIDNEY DISEASE; LIVER DISEASE; LIVER DYSFUNCTION; LIVER TOXICITY; LYMPHADENOPATHY; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MULTIDRUG RESISTANCE; NAUSEA AND VOMITING; PAIN; PNEUMONIA; POSTMARKETING SURVEILLANCE; PREGNANCY; QUALITY OF LIFE; RASH; RESPIRATORY DISTRESS; RIGOR; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRUS ENTRY; VIRUS LOAD;

CLINICAL TRIALS, PHASE III AS TOPIC; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; PEPTIDE FRAGMENTS; PRODUCT SURVEILLANCE, POSTMARKETING; QUALITY OF LIFE;

EID: 52349123067     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.13.2349     Document Type: Article

References (134)

1. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, 2008. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf [Last accessed 16 February 2008]
2. FDA approves first drug in new class of HIV treatments for HIV infected adults and children with advanced disease, 2003. Available from: http://www.fda.gov/bbs/topics/NEWS/2003/NEW00879.html [Last accessed 19 February 2008]
3. FDA approves new therapy for HIV patients with advanced disease. FDA News. 2005. Available from: http://www.fda.gov/bbs/topics/NEWS/2005/ NEW01189.html [Last accessed 19 February 2008]
4. FDA approves new HIV drug: raltegravir tablets used in combination with other antiretroviral agents. FDA News. 2006. Available from: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01726.html [Last accessed 19 February 2008]
5. FDA approves new HIV treatment for patients who do not respond to existing drugs. FDA News. 2006. Available from: http://www.fda.gov/bbs/ topics/NEWS/2006/NEW01395.html [Last accessed February 19 2008]
6. FDA approves novel antiretroviral drug. FDA News. 2007. Available from: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01677.html [Last accessed February 19 2008]
7. FDA approves new HIV drug after priority review: etravirine tablets used in combination with other antiretroviral agents. FDA News. 2008. Available from: http://www.fda.gov/bbs/topics/NEWS/2008/NEW01783.html [Last accessed 19 February 2008]
8. Walmsley SL. Advances in the management of treatment experienced patients: a 2nd wave of HAART. Proceedings of the 15th Conference on Retroviruses and Opportunistic Infections (CROI); 7 February 2008; Boston, Massachusetts, USA
9. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348(22):2175-85
10. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348(22):2186-95
11. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the randomized evaluation of strategic intervention in multi-drug reSistant patients with tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006;368(9534):466-75
12. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007;369(9568):1169-78
13. Haubrich R, Cahn P, Grinsztejn B, et al. DUET-1: week 48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of etravirine (ETR; TMC125) versus placebo in 612 treatment-experienced HIV-1-infected patients [abstract 790]. Proceedings of the 15th Conference on Retroviruses and Opportunistic Infections (CROI); 3-6 February 2008; Boston, Massachusetts, USA
14. Johnson M, Campbell T, Clotet B, et al. DUET-2: week-48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs. placebo in 591 treatment-experienced HIV-1-infected patients [abstract 791]. Proceedings of the 15th Conference on Retroviruses and Opportunistic Infections (CROI). 3-6 February 2008; Boston, Massachusetts, USA
15. Cooper DA, Gatell J, Rockstroh J, et al. 48-Week results from BENCHMRK-1, a phase III study of raltegravir (RAL) in patients failing antiretroviral therapy (ART) with triple-class resistant HIV-1 [abstract 788]. 15th Conference on Retroviruses and Opportunistic Infections (CROI); 3-6 February 2008; Boston, Massachusetts, USA
16. Steigbigel R, Kumar P, Eton J, et al. 48-Week results from BENCHMRK-2, a phase III study of raltegravir in patients failing ART with triple-class resistant HIV [abstract 789]. Proceedings of the 15th Conference on Retroviruses and Opportunistic Infections (CROI); 3-6 February 2008; Boston, Massachusetts, USA
17. Lalezari J, Goodrich J, DeJesus E, et al. Efficacy and safety of maraviroc in antiretroviral experienced patients infected with CCR5 tropic HIV-1: 48 week results of Motivate 1 [presentation number H-718a]. 47th ICAAC; 17-20 September 2007; Chicago, Illinois, USA
18. Trottier B, Walmsley S, Reynes J, et al. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr 2005;40(4):413-21
19. Ruxrungtham K, Boyd M, Bellibas SE, et al. Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients. J Clin Pharmacol 2004;44(7):793-803
20. Boyd MA, Zhang X, Dorr A, et al. Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide. J Clin Pharmacol 2003;43(12):1382-91
21. Zhang X, Lalezari JP, Badley AD, et al. Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients. Clin Pharmacol Ther 2004;75(6):558-68
22. Gonzalez de Requena D, Calcagno A, Bonora S, et al. Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide. AIDS 2006;20(15):1977-9
23. Raffi F, Battegay M, Rusconi S, et al. Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST AIDS 2007;21(14):1977-80
24. Curran A, Lopez R, Pou L, et al. Pharmacokinetic evaluation of potential interaction between tipranavir and enfuvirtide [abstract 53]. Proceedings of the 7th international workshop on clinical pharmacology of HIV therapy. 20-22 April 2006; Lisbon, Portugal
25. Sekar V, De Paepe E, Vangeneugden T, et al. Absence of an interaction between the potent HIV protease inhibitor TMC114 and the fusion inhibitor enfuvirtide in the POWER 3 analysis [abstract 54]. 7th International Workshop on Clinical Pharmacology of HIV Therapy; 20-22 April 2006; Lisbon, Portugal
26. Lu J, Deeks SG, Hoh R, et al. Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J Acquir Immune Defic Syndr 2006;43(1):60-4
27. Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002;46(6):1896-905
28. Roche Laboratories Inc. and Trimeris, Inc. Fuzeon full prescribing information, 2007. Available from: http://www.rocheusa.com/products/ fuzeon/pi.pdf [Last accessed 19 February 2008]
29. Bray BL. Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat Rev Drug Discov 2003;2(7):587-93
30. Castagna A, Biswas P, Beretta A, et al. The appealing story of HIV entry inhibitors: from discovery of biological mechanisms to drug development. Drugs 2005;65(7):879-904
31. Tashima KT, Carpenter CC. Fusion inhibition - a major but costly step forward in the treatment of HIV-1. N Engl J Med 2003;348(22):2249-50
32. Deng Y, Zheng Q, Ketas TJ, et al. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor. Biochemistry 2007;46(14):4360-9
33. Pierson TC, Doms RW. HIV-1 entry and its inhibition. Curr Top Microbiol Immunol 2003;281:1-27
34. Eckert DM, Kim PS. Mechanisms of viral membrane fusion and its inhibition. Ann Rev Biochem 2001;70:777-810
35. Moyle G. Stopping HIV fusion with enfuvirtide: the first step to extracellular HAART. J Antimicrob Chemother 2003;51(2):213-7
36. LaBranche CC, Galasso G, Moore JP, et al. HIV fusion and its inhibition. Antiviral Res 2001;50(2):95-115
37. Este JA. Virus entry as a target for anti-HIV intervention. Curr Med Chem 2003;10(17):1617-32
38. Briz V, Poveda E, Soriano V. HIV entry inhibitors: mechanisms of action and resistance pathways. J Antimicrob Chemother 2006;57(4):619-27
39. Este JA, Telenti A. HIV entry inhibitors. Lancet 2007;370(9581):81-8
40. Liu S, Lu H, Niu J, et al. Different from the HIV fusion inhibitor C34, the anti-HIV drug fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem 2005;280(12):11259-73
41. Holguin A, Faudon JL, Labernardiere JL, et al. Susceptibility of HIV-1 non-B subtypes and recombinant variants to enfuvirtide. J Clin Virol 2007;38(2):176-80
42. Fleury HJ, Toni T, Lan NT, et al. Susceptibility to antiretroviral drugs of CRF01Æ, CRF02_AG, and subtype C viruses from untreated patients of Africa and Asia: comparative genotypic and phenotypic data. AIDS Res Hum Retroviruses 2006;22(4):357-66
43. Cilliers T, Patience T, Pillay C, et al. Sensitivity of HIV type 1 subtype C isolates to the entry inhibitor T-20. AIDS Res Hum Retroviruses 2004;20(5):477-82
44. Chinnadurai R, Munch J, Dittmar MT, et al. Inhibition of HIV-1 group M and O isolates by fusion inhibitors. AIDS 2005;19(16):1919-22
45. Poveda E, Barreiro P, Rodes B, et al. Enfuvirtide is active against HIV type 1 group O. AIDS Res Hum Retroviruses 2005;21(6):583-5
46. Melby T, Sista P, DeMasi R, et al. Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. AIDS Res Hum Retroviruses 2006;22(5):375-85
47. Poveda E, Rodes B, Toro C, et al. Are fusion inhibitors active against all HIV variants? AIDS Res Hum Retroviruses 2004;20(3):347-8
48. Witvrouw M, Pannecouque C, Switzer WM, et al. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 2004;9(1)57-65
49. Zhang X, Nieforth K, Lang JM, et al. Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: inverse Gaussian density absorption and 2-compartment disposition. Clin Pharmacol Ther 2002;72(1):10-9
50. Lalezari JP, Patel IH, Zhang X, et al. Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients. J Clin Virol 2003;28(2):217-22
51. Harris M, Joy R, Larsen G, et al. Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector). AIDS 2006;20(5):719-23
52. True AL, Chiu YY, Demasi RA, et al. Pharmacokinetic bioequivalence of enfuvirtide using a needle-free device versus standard needle administration. Pharmacotherapy 2006;26(12):1679-86
53. Ghosn J, Chaix ML, Peytavin G, et al. Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS 2004;18(14):1958-61
54. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008;65(1):65-70
55. + pregnant women [abstract 627b]. 15th Conference on Retroviruses and Opportunistic Infections (CROI); 3-6 February 2008; Boston, Massachusetts, USA
56. Stocker H, Kloft C, Plock N, et al. Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings. Antimicrob Agents Chemother 2006;50(2):667-73
57. Mould DR, Zhang X, Nieforth K, et al. Population pharmacokinetics and exposure response relationship of enfuvirtide in treatment experienced human immunodeficiency virus type 1 infected patients. Clin Pharmacol Ther 2005;77:515-28
58. Gonzalez de Requena D, Bonora S, Castagna A, et al. Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients. Journal of Antimicrobial Chemotherapy 2008;62(2):384-387
59. Tebas P, Bellos N, Lucasti C, et al. Enfuvirtide does not require dose adjustment in patients with chronic kidney failure: results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with impaired kidney function. J Acquir Immune Defic Syndr 2008;47(3):342-5
60. Bellibas SE, Siddique Z, Derr A, et al.; T20-310/NV16056 Study Group. Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy. Pediatr Infect Dis J 2004;23(12):1137-41
61. Zhang X, Lin T, Bertasso A, et al.; T20-310/NV16056 Study Group. Population pharmacokinetics of enfuvirtide in HIV-1-infected pediatric patients over 48 weeks of treatment. J Clin Pharmacol 2007;47(4):510-7
62. Meyohas MC, Lacombe K, Carbonne B, et al. Enfuvirtide prescription at the end of pregnancy to a multi-treated HIV-infected woman with virological breakthrough. AIDS 2004;18(14):1966-8
63. Cohan D, Feakins C, Wara D, et al. Perinatal transmission of multidrug-resistant HIV-1 despite viral suppression on an enfuvirtide-based treatment regimen. AIDS 2005;19(9):989-90
64. Brennan-Benson P, Pakianathan M, Rice P, et al. Enfurvitide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross the placenta. AIDS 2006;20(2):297-9
65. Thompson M, DeJesus E, Richmond G, et al. Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects. AIDS 2006;20(3):397-404
66. Patel IH, Zhang X, Nieforth K, et al. Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin Pharmacokinet 2005;44(2):175-86
67. Hall D, Scherer J, Schapiro J, et al. Genotypic relationships between tipranavir and darunavir resistance in protease inhibitor experienced patients [abstract 79]. Proceedings of the 16th international HIV drug resistance workshop; 12-16 June 2007; Barbados, West Indies
68. Melby T, Sista P, DeMasi R, et al. Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. AIDS Res Hum Retroviruses 2006;22(5):375-85
69. Sista PR, Melby T, Davison D, et al. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 2004;18(13):1787-94
70. Poveda E, Rodes B, Lebel-Binay S, et al. Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy. J Clin Virol 2005;34(4):295-301
71. Xu L, Pozniak A, Wildfire A, et al. Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob Agents Chemother 2005;49(3):1113-9
72. Perez-Alvarez L, Carmona R, Ocampo A, et al. Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1. J Med Virol 2006;78(2):141-7
73. Su C, Melby T, DeMasi R, et al. Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro. J Clin Virol 2006;36(4):249-57
74. Aquaro S, D'Arrigo R, Svicher V, et al. Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. J Antimicrob Chemother 2006;58(4):714-22
75. Trabaud MA, Cotte L, Labernardiere JL, et al. Variants with different mutation patterns persist in the quasispecies of enfuvirtide-resistant HIV-1 population during and after treatment in vivo. J Acquir Immune Defic Syndr 2007;46(2):134-144
76. Reeves JD, Gallo SA, Ahmad N, et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci USA 2002;99(25):16249-54
77. Derdeyn CA, Decker JM, Sfakianos JN, et al. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J Virol 2001;75(18):8605-14
78. Whitcomb J, Huang W, Fransen S, et al. Analysis of baseline enfuvirtide (T-20) susceptibility and co-receptor tropism in two phase III study populations [abstract 557]. Proceedings of the 10th Conference on Retroviruses and Opportunistic Infections (CROI); 10-14 February 2003; Boston, Massachusetts, USA
79. Reeves JD, Lee FH, Miamidian JL, et al. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J Virol 2005;79(8):4991-9
80. Deeks SG, Lu J, Hoh R, et al. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen. J Infect Dis 2007;195(3):387-91
81. Chibo D, Roth N, Roulet V, et al. Virological fitness of HIV in patients with resistance to enfuvirtide. AIDS 2007;21(14):1974-7
82. Labrosse B, Morand-Joubert L, Goubard A, et al. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. J Virol 2006;80(17):8807-19
83. Vicher V, Aquaro S, D'Arrigo R, et al. Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure. J Infect Dis 2008;197(10):1408-18
84. Melby TE, Despirito M, Demasi RA, et al. Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy. AIDS 2007;21(18):2537-9
85. Marcial M, Lu J, Deeks SG, et al. Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations. J Clin Microbiol 2006;44(9):3384-7
86. Van Laethem K, Schrooten Y, Lemey P, et al. A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope gene. J Virol Methods 2005;123(1):25-34
87. Fung HB, Guo Y. Enfuvirtide: a fusion inhibitor for the treatment of HIV infection. Clin Ther 2004;26(3):352-78
88. Lazzarin A. Enfuvirtide: the first HIV fusion inhibitor. Expert Opin Pharmacother 2005;6(3):453-64
89. Oldfield V, Keating GM, Plosker G. Enfuvirtide: a review of its use in the management of HIV infection. Drugs 2005;65(8):1139-60. Erratum appears in: Drugs 2005;6512:1667
90. Jamjian MC, McNicholl IR. Enfuvirtide: first fusion inhibitor for treatment of HIV infection. Am J Health-System Pharm 2004;61(12):1242-7
91. Nelson M, Arasteh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005;40(4):404-12
92. Reynes J, Arasteh K, Clotet B, et al. TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. AIDS Patient Care STDS 2007;21(8):533-43
93. Walmsley S, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in subgroups of patients through 48 weeks of therapy in the TORO trials [abstract no. 7.3/15 plus poster]. Proceedings of the 9th European AIDS Conference and 1st EACS resistance and pharmacology workshop; 25-29 October 2003; Warsaw, Poland
94. Montaner J, DeMasi R, Delehanty J, et al. Analysis of virological response of enfuvirtide in TORO: implications for patient management. 2nd International Aids Society Conference in HIV Pathogenesis and Treatment [abstract 116]. Antiviral Ther 2003;8 (Suppl 1): 212
95. Bartlett J, Salgo M, DeMasi R. Early viral load responses on enfuvirtide in heavily treatment-experienced patients [abstract TuPeB4484]. Proceedings of the 15th International AIDS Conference. 11-16 July 2004; Bangkok, Thailand
96. Witek J, Rockstroh J, Donatacci L, et al. Adherence to enfuvirtide and to background antiretroviral therapy over 48 weeks and its impact on treatment efficacy [abstract WePeB5822]. Proceedings of the 15th International AIDS Conference; 11-16 July 2004; Bangkok, Thailand
97. Clotet B, Capetti A, Soto-Ramirez L, et al. An intensification treatment strategy of adding enfuvirtide to an oral HAART regimen: the INTENSE study 24 week induction phase analysis [poster P4.3/73]. 11th European Aids Conference (EACS); 24-27 October 2007; Madrid, Spain.
98. Wright D, Rodriguez A, Godofsky E, et al. Efficacy and safety of 48 weeks of enfuvirtide 180 mg once-daily dosing versus 90 mg twice-daily dosing in HIV-infected patients. HIV Clin Trials 2008;9(2):73-82
99. Wright D, Rodriguez A, Godofsky E, et al. A pilot 48-week study of once-daily (180 mg QD) versus twice-daily (90 mg BID) enfuvirtide [poster P30]. Proceedings of the 8th International Congress on Drug Therapy in HIV infection. 12-16 November 2006; Glasgow, Scotland
100. Wiznia A, Church J, Emmanuel P, et al. Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients. Pediatr Infect Dis J 2007;26(9):799-805
101. Cooper D; On behalf of the Alliance Investigator Group. An analysis of the correlation between the severity of injection site reactions and the amount of subcutaneous fat in the alliance cohort [abstract 838]. Proceedings of the 12th Conference on Retroviruses and Opportunistic Infections (CROI); 22-25 February 2005; Boston, Massachusetts, USA
102. Shalit P, True A, Thommes JA, et al. Quality of life and tolerability after administration of enfuvirtide with a thin-walled needle: QUALITE study. HIV Clin Trials 2007;8(1):24-35
103. Gottlieb M, True A, Evans R, et al. Needle-free administration (biojector) or enfuvirtide significantly reduces incidence of painful injection site reactions: results from a single blind, randomized, controlled study [abstract H-1905b]. 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 27-30 September 2006; San Francisco, California, USA
104. Quiros-Roldan E, Tirelli V, Torti C, et al. Successful long-course after failure of short-course desensitization in a patient with severe hypersensitivity reaction to enfuvirtide. AIDS 2007;21(10):1388-9
105. Shahar E, Moar C, Pollack S. Successful desensitization of enfuvirtide-induced skin hypersensitivity reaction. AIDS 2005;19(4):451-2
106. DeSimone JA, Ojha A, Pathak R, et al. Successful desensitization to enfuvirtide after a hypersensitivity reaction in an HIV-1-infected man. Clin Infect Dis 2004;39(10):e110-2
107. Machado ES, Passoni LF, Sidi LC, et al. Successful desensitization of enfuvirtide after a first attempt failure. AIDS 2006;20(16):2130-1
108. Polizzotto MN, Street AM, Wright E. The safety and efficacy of enfuvirtide therapy for HIV infection in patients with hemophilia: a case series. Clin Infect Dis 2007;45(4):e39-41
109. Walmsley S, Henry K, Katlama C, et al. Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide. J Infect Dis 2003;188(12):1827-33
110. Cohen C, Green J, Wintfeld N, et al. Patient acceptance of self-injected enfuvirtide for HIV over 48 weeks of treatment [abstract 7. 1/1 plus poster]. 9th European Aids Conference (EACS); 25-29 October 2003; Warsaw, Poland
111. Clumeck N, Cohen CJ, Thompson M, et al. Impact of enfuvirtide on health-related quality of life at 48 weeks [abstract 7.3/19]. Proceedings of the 9th European Aids Conference (EACS); 25-29 October 2003; Warsaw, Poland
112. Cohen CJ, Clumeck N, Molina JM, et al. Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimen. J Acquit Immune Defic Syndr 2004;37(1):1140-6
113. Loutfy MR, Harris M, Raboud JM, et al. A large prospective study assessing injection site reactions, quality of life and preference in patients using the biojector vs. standard needles for enfuvirtide administration. HIV Med 2007;8(7):427-32
114. Baylor MS, Johann-Liang R. Enfurvirtide safety in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2005;24(4):389-90
115. Wiznia A, Church J, Emmanuel P, et al. 24-week safety and efficacy of enfuvirtide as part of an optimized ART regimen in children [abstract 765]. Proceedings of the 12th Conference on Retroviruses and Opportunistic Infections (CROI); 22-25 February 2005; Boston, Massachusetts, USA
116. Church JA, Cunningham C, Hughes M, et al. Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children. Pediatr Infect Dis J 2002;21(7):653-9
117. Church JA, Hughes M, Chen J, et al. Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children. Pediatr Infect Dis J 2004;23(8):713-8
118. Wiznia A, Church J, Stavola J, et al. 24-Week safety and efficacy of enfuvirtide as part of an optimized antiretroviral regimen in adolescents [abstract 929]. Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections (CROI). 8-11 February 2004; San Francisco, California, USA
119. Tseng A, Marr P. Drug interaction tables, Toronto General Hospital immunodeficiency clinic. Available from: http://www.tthhivclinic.com/ interact_tables.html [Accessed 12 July 2008]
120. Darunavir ethalolate (marketed as prezista) information; FDA alert. US Food and Drug Administration, 21 March 2008. Available from: http://www.fda.gov/cder/drug/infopage/darunavir/default.htm [Last accessed 5 April 2008]
121. Aptivus prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc., Oct 2007. Available from: http://bidocs.boehringer-ingelheim.com/ BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/ Prescribing+Information/PIs/Aptivus/10003515+US+01.pdf [Last accessed 5 April 2008]
122. Vingerhoets J, Peeters M, Corbett C, et al. Effect of baseline resistance on the virologic response to a novel NNRTI, TMC125, in patients with extensive NNRTI and PI resistance: analysis of study TMCI25-223 [abstract 154]. Proceedings of the 13th Conference on Retroviruses and Opportunistic Infections (CROI); 5-8 February 2006; Denver, Colorado, USA
123. Vingerhoets J, Buelens A, Peeters M, et al. Impact of baseline NNRTI mutations on the virological response to TMC125 in the phase III clinical trials DUET-1 and DUET-2 [abstract 32]. Proceedings of the 16th international HIV drug resistance workshop; 12-16 June 2007; Barbados, West Indies
124. Scholler M, Kraft M, Hoetelmans R, et al. Significant decrease in TMC125 exposures when co-adminiscered with tipranavir boosted with ritonavir in healthy subjects [abstract 583]. Proceedings of the 13th Conference on Retroviruses and Opportunistic Infections (CROI); 5-8 February 2006; Denver, Colorado, USA
125. Harris M, Larsen G, Montaner JSG. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. AIDS 2008;22(10):1224-6
126. Raltegravir substitution for enfuvirtide in patients suffering from injection site reactions (ISRs): the Raleve pilot study, 2008. Available from: http://clinicaltrials.gov/ct2/show/ NCT00523237?intr=%22Enfuvirtide%22&rank=37 [Last accessed 8 June 2008]
127. Efficacy and tolerance of the switch from enfuvirtine to raltegravir in antiretroviral therapy regimen in HIV patients with undetectable viral load (EASIER). Available from: http://clinicaltrials.gov/ct2/show/ NCT00454337?term=easier+study&rank=1 [Last accessed 8 June 2008]
128. Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects (CHEER). Available from: http://clinicaltrials.gov/ct2/ show/NCT00529243?term=cheer&rank=2 [Last accessed 23 July 2008]
129. Carter NJ, Keating GM. Maraviroc. Drugs 2007;67(15):2277-88
130. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005;49(11):4721-32
131. Crabb C. GlaxoSmithKline ends aplaviroc trials. AIDS 2006;20(5):641
132. Mayer H. Maraviroc: a case of severe hepatotoxicity. First International Workshop on Targeting HIV Entry; 2-3 December 2005; Bethesda, Maryland, USA
133. Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007;196(2):304-12
134. Aquaro S, Svicher V, D'Arrigo R, et al. Characterization of Gp41 evolution in a large cohort of HIV-1-infected patients receiving long-term T-20 treatment as a single active drug [abstract 596]. Proceedings of the 13th Conference on Retroviruses and Opportunistic Infections (CROI); 5-8 Feb 2006; Denver, Colorado, USA